Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Le point sur le dépistage du cancer de la prostate par le PSA.

Title :
Le point sur le dépistage du cancer de la prostate par le PSA.
Index Terms :
Sciences bio-médicales et agricoles
Digital Rectal Examination
Early Detection of Cancer -- methods
Humans
Male
Practice Guidelines as Topic
Prostate-Specific Antigen -- blood
Prostatic Neoplasms -- blood -- diagnosis -- epidemiology
Biomarkers
Mass screening
PCA3
Phi
Prostate cancer
PSA isoforms
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
Publisher :
2013-09
Added Details :
Roumeguere, Thierry
Van Velthoven, Roland
Document Type :
Electronic Resource
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/156458
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Availability :
Open access content. Open access content
Other Numbers :
EQY oai:dipot.ulb.ac.be:2013/156458
uri/info:pmid/24195246
uri/info:scp/84888600631
872086389
Contributing Source :
UNIV LIBR DE BRUXELLES
From OAIster®, provided by the OCLC Cooperative.
Accession Number :
edsoai.ocn872086389
Electronic Resource
Prostate cancer detection is mainly based on PSA serum levels and digital rectal examination. The wide use of PSA with time led to increased prostate cancer incidence in the highest ressources countries worldwide with less mortality rates compared to less developed regions of the world. Screening for prostate cancer is among the most controversial topics in the field of urology. US Preventive Services Task Force recently finalized a crisp recommendation that routine PSA-based screening should be stopped. Results from the ERSPC study of screening for prostate cancer reported the impact of PSA testing in reducing cancer-specific mortality but with a higher rate of localized tumour detection with better prognostic factors. Scientific societies have elaborated their recommendations in favour of a share decision making with patients with at least 10 to 15 years of life expectancy. In view of the unsatisfactory accuracy of the two diagnostic exams, strategies to reduce PSA-driven prostate cancer overdiagnosis and overtreatment seem to be necessary. Research has focused on novel markers to improve pre-biopsy prostate cancer detection, such as prostate health index (phi) and PCA3. In patients with a total PSA range of 2-10 ng/ml, phi and PCA3 seem to be the strongest predictors of prostate cancer at initial biopsy and are significantly more accurate than total PSA and percentage free PSA.
English Abstract
Journal Article
Review
SCOPUS: ar.j
info:eu-repo/semantics/published

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.